Diabetic Nephropathy Type 2NCT07498894
Salivary and Serum Inflammatory Biomarkers in Diabetic Nephropathy by Periodontal Status
An observational study of Diabetic Nephropathy Type 2 and Type 2 Diabetes, run by Pamukkale University at 1 site in Turkey (Türkiye).
Trial summary
Chronic inflammation underlies the bidirectional relationship between diabetes and periodontitis, a process that may be further exacerbated in the presence of diabetic nephropathy. Read more about this study
- Who is it for?
- Ages 20 to 75 years
- Conditions the study is for
- Diabetic Nephropathy Type 2, Type 2 Diabetes, Periodontitis
- What is being tested?
- clinical periodontal measurements, serum samples and saliva samples
- How many people
- 126 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 10 Jun 2024to 12 Dec 2025
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Newly diagnosed type 2 diabetic subjects were recruited from patients diagnosed with type 2 diabetes for less than 5 years attending the outpatient clinic of the Department of Endocrinology, Pamukkale University Hospital and subsequently referred to the Department of Periodontology. Following periodontal examination, participants were diagnosed as periodontally healthy, gingivitis, or periodontitis, and were allocated to the corresponding study groups according to their periodontal status.
Who may be able to join
- Newly diagnosed diabetes: Diagnosed with type 2 diabetes mellitus for less than 5 years and the absence of any diabetic vascular complications
- Diabetic nephropathy: Urinary albumin-to-creatinine ratio >30 mg/g
Who cannot join
- Having fewer than 15 natural teeth
- Pregnancy or lactation
- History of malignancy
- Use of systemic antibiotics or anti-inflammatory drugs within the 6 months prior to study enrollment
- Periodontal treatment within the previous 6 months
- Type 1 diabetes mellitus, gestational diabetes mellitus, or secondary diabetes mellitus
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Pamukkale University Faculty of Dentistry
Denizli, 20160
About this study
Official title: Salivary and Serum Inflammatory Biomarkers Based on Periodontal Status in Individuals With Diabetic Nephropathy
Chronic inflammation underlies the bidirectional relationship between diabetes and periodontitis, a process that may be further exacerbated in the presence of diabetic nephropathy. While the roles of inflammatory cytokines such as TNF-α and IL-10 in both periodontal tissue destruction and diabetes-related microvascular complications remain unclear, NGAL is recognized as a biomarker for diabetic nephropathy but its association with periodontal disease is not well established. This study aimed to comparatively evaluate salivary and serum levels of NGAL, TNF-α, and IL-10 according to different periodontal conditions in individuals with newly diagnosed diabetes and those with diabetic nephropathy.
Read the detailed description
The newly diagnosed diabetes mellitus group consisted of patients attending the Department of Endocrinology who had been diagnosed with type 2 diabetes mellitus for less than 5 years and had no evidence of diabetic vascular complications. The diabetic nephropathy group comprised patients followed in the Department of Endocrinology for nephropathy, defined as a urinary albumin-to-creatinine ratio >30 mg/g.
At baseline, height, body weight, and waist circumference were measured, and body mass index (BMI) was calculated. The body mass index (BMI) was calculated by taking the weight, in kilograms divided by the height in meters squared. A complete physical examination was also performed. In patients evaluated for diabetes mellitus, routinely requested laboratory parameters, including fasting plasma glucose, insulin, HOMA-IR, glycated haemoglobin (HbA1c), complete blood count, liver and renal function tests, erythrocyte sedimentation rate, C-reactive protein (CRP), estimated glomerular filtration rate (eGFR), triglycerides, total cholesterol, HDL, LDL, TSH, and urinary albumin-to-creatinine ratio, were retrieved from the hospital information management system and recorded. Subsequently, all patients were referred to the Faculty of Dentistry, Pamukkale University for further periodontal evaluation.
Following periodontal examination, participants were diagnosed as periodontally healthy, gingivitis, or periodontitis, and were allocated to the corresponding study groups according to their periodontal status. The periodontal status of patients was determined based on the Classification of Periodontal and Peri-Implant Diseases and Conditions stated in 2017 World Workshop. Periodontally health was considered if the volunteers have clinically healthy gingiva on an intact periodontium who had BOP < 10% and PD ≤ 3 mm, no sites with attachment loss, no radiographic sign of alveolar bone destruction and no history of periodontitis. Gingivitis was characterized by the absence of clinical attachment loss and radiographic bone loss, with a BOP score ≥10% (gingivitis on an intact periodontium). Patients with periodontitis were defined as individuals presenting with periodontal disease characterized by PD ≥6 mm, interdental clinical attachment loss (CAL) ≥5 mm, and radiographic bone loss extending to the middle third of the root or beyond in ≥30% of teeth. In these patients, the number of teeth lost due to periodontitis was ≤4.
In Endocrinology clinic, peripheral venous blood samples were collected from all included participants via the antecubital vein. A total of 10 mL of venous blood was obtained using separator vacutainer tubes and centrifuged at room temperature. Unstimulated whole saliva was collected by passive drooling into a sterile test tube over a 10-minute period in Periodontology clinic. The collected serum and saliva samples were transferred into Eppendorf tubes and stored at -80°C until the day of analysis.
The concentrations of NGAL, TNF-α, and IL-10 in serum and saliva samples were measured using the enzyme-linked immunosorbent assay (ELISA) method at the Department of Histology and Embryology.
The power analyse of the study was performed for sample size calculation. Sample size was calculated using the G*Power software program (G*Power; Universitat, Dusseldorf, Germany) for α = 0.05 and f = 0.4. The analyses revealed that 19 subjects per group achieved a power of 80 % with 95% confidence.
The data were analysed with the SPSS 25 program (SPSS Inc., Chicago, IL). Continuous variables were presented as mean ± standard deviation and categorical variables as numbers and percentages. Shapiro-Wilk test was used to detect data's normality. For the comparison of the parameters of the study groups, One-way ANOVA test was used for normally distributed data while Kruskal-Wallis test was performed as non-parametric test. For pairwise group comparisons, Student's t-test or the Mann-Whitney U test was applied. Chi-square test was used for the comparison of the categorical variables. Statistical significance value was considered as p < 0.05.
- Conditions
- Diabetic Nephropathy Type 2, Type 2 Diabetes, Periodontitis, Gingivitis, Periodontal Health
- Being tested
- clinical periodontal measurements, serum samples, saliva samples
- Keywords
- diabetic nephropathy, periodontitis, NGAL, cytokine, saliva
- Medical subject headings
- Diabetes Mellitus, Type 2, Periodontitis, Gingivitis, Diabetic Nephropathies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
clinical periodontal measurementsDiagnostic test
Periodontal parameters such as PI, GI, BOP, PD, and CAL were measured using the Williams periodontal probe (Hu-Friedy, Chicago IL). PD and CAL were calculated at six surfaces per tooth, whereas PI and GI were measured at four surfaces per tooth.
the periodontal status of patients was determined based on the Classification of Periodontal and peri-implant diseases and conditions stated in 2017 World Workshop
serum samplesDiagnostic test
Peripheral blood samples were obtained from the antecubital vein. A total of 10 mL of venous blood was collected using separator vacutainer tubes and centrifuged at room temperature. The obtained serum was transferred into separate Eppendorf tubes. The tubes were sealed with parafilm, labeled, and stored at -80°C until the day of analysis.
NGAL, TNF-alpha and IL-10 levels were analyzed with ELISA method
saliva samplesDiagnostic test
Unstimulated whole saliva samples were collected using the passive drooling method into a sterile collection tube over a 10-minute period.The obtained saliva was transferred into separate Eppendorf tubes. The tubes were sealed with parafilm, labeled, and stored at -80°C until the day of analysis.
NGAL, TNF-alpha and IL-10 levels were analyzed with ELISA method
| Study group | Role | What they receive |
|---|---|---|
| newly diagnosed type 2 diabetes and periodontal health | 21 participants with newly diagnosed type 2 diabetes and periodontal health were recruited in group 1. The clinical periodontal parameters taken are as follows: plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL). The present number of teeth in participants was recorded. Serum and saliva samples were collected for the analysis of biomarkers such as NGAL, IL-10, and TNF-α. Receives: Diagnostic Test: clinical periodontal measurements; Diagnostic Test: serum samples; Diagnostic Test: saliva samples | |
| newly diagnosed type 2 diabetes and gingivitis | 20 participants with newly diagnosed type 2 diabetes and gingivitis were recruited in group 2. The clinical periodontal parameters taken are as follows: plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL). The present number of teeth in participants was recorded. Serum and saliva samples were collected for the analysis of biomarkers such as NGAL, IL-10, and TNF-α. Receives: Diagnostic Test: clinical periodontal measurements; Diagnostic Test: serum samples; Diagnostic Test: saliva samples | |
| newly diagnosed type 2 diabetes and periodontitis | 22 participants with newly diagnosed type 2 diabetes and gingivitis were recruited in group 3. The clinical periodontal parameters taken are as follows: plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL). The present number of teeth in participants was recorded. Serum and saliva samples were collected for the analysis of biomarkers such as NGAL, IL-10, and TNF-α. Receives: Diagnostic Test: clinical periodontal measurements; Diagnostic Test: serum samples; Diagnostic Test: saliva samples | |
| diabetic nephropathy and periodontal health | 21 participants with diabetic nephropathy and periodontal health were recruited in group 4. The clinical periodontal parameters taken are as follows: plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL). The present number of teeth in participants was recorded. Serum and saliva samples were collected for the analysis of biomarkers such as NGAL, IL-10, and TNF-α. Receives: Diagnostic Test: clinical periodontal measurements; Diagnostic Test: serum samples; Diagnostic Test: saliva samples | |
| diabetic nephropathy and gingivitis | 20 participants with diabetic nephropathy and gingivitis were recruited in group 5. The clinical periodontal parameters taken are as follows: plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL). The present number of teeth in participants was recorded. Serum and saliva samples were collected for the analysis of biomarkers such as NGAL, IL-10, and TNF-α. Receives: Diagnostic Test: clinical periodontal measurements; Diagnostic Test: serum samples; Diagnostic Test: saliva samples | |
| diabetic nephropathy and periodontitis | 22 participants with diabetic nephropathy and gingivitis were recruited in group 6. The clinical periodontal parameters taken are as follows: plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL). The present number of teeth in participants was recorded. Serum and saliva samples were collected for the analysis of biomarkers such as NGAL, IL-10, and TNF-α. Receives: Diagnostic Test: clinical periodontal measurements; Diagnostic Test: serum samples; Diagnostic Test: saliva samples |
What is being measured
The primary outcome is the main question the study is designed to answer.
NGAL analysis
Mean NGAL levels (ng/ml) in serum and saliva
Measured: baseline
Secondary outcomes (2)
TNF-alpha analysis
Mean TNF-alpha levels (ng/L)in serum and saliva
Measured: baseline
IL-10 analysis
Mean IL-10 levels (ng/ml) in serum and saliva
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Mar 2026
- Study start10 Jun 2024
- Primary completion12 Dec 2025
- Study completion12 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetic Nephropathy Type 2Studies of the same condition, open and under way.
- More trials run by Pamukkale UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 126 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Pamukkale University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gizem Torumtay Cin, Pamukkale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07498894
- Sponsor's protocol ID
- 2024HZDP005
- Status last verified
- Mar 2026
- First submitted
- 23 Mar 2026
- Last updated
- 27 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Salivary and Serum Inflammatory Biomarkers Based on Periodontal Status in Individuals With Diabetic Nephropathy
- ClinicalTrials.gov ID
- NCT07498894
- Acronym / sponsor ID
- 2024HZDP005
- Conditions
- Diabetic Nephropathy Type 2, Type 2 Diabetes, Periodontitis, Gingivitis, Periodontal Health
- Keywords
- diabetic nephropathy, periodontitis, NGAL, cytokine, saliva
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 126 participants (actual)
- Lead sponsor
- Pamukkale UniversityUniversity, hospital or other
- Study start
- 10 Jun 2024 (actual)
- Primary completion
- 12 Dec 2025 (actual)
- Study completion
- 12 Dec 2025 (actual)
- First posted
- 27 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic inflammation underlies the bidirectional relationship between diabetes and periodontitis, a process that may be further exacerbated in the presence of diabetic nephropathy. While the roles of inflammatory cytokines such as TNF-α and IL-10 in both periodontal tissue destruction and diabetes-related microvascular complications remain unclear, NGAL is recognized as a biomarker for diabetic nephropathy but its association with periodontal disease is not well established. This study aimed to comparatively evaluate salivary and serum levels of NGAL, TNF-α, and IL-10 according to different periodontal conditions in individuals with newly diagnosed diabetes and those with diabetic nephropathy.
Detailed description
The newly diagnosed diabetes mellitus group consisted of patients attending the Department of Endocrinology who had been diagnosed with type 2 diabetes mellitus for less than 5 years and had no evidence of diabetic vascular complications. The diabetic nephropathy group comprised patients followed in the Department of Endocrinology for nephropathy, defined as a urinary albumin-to-creatinine ratio >30 mg/g.
At baseline, height, body weight, and waist circumference were measured, and body mass index (BMI) was calculated. The body mass index (BMI) was calculated by taking the weight, in kilograms divided by the height in meters squared. A complete physical examination was also performed. In patients evaluated for diabetes mellitus, routinely requested laboratory parameters, including fasting plasma glucose, insulin, HOMA-IR, glycated haemoglobin (HbA1c), complete blood count, liver and renal function tests, erythrocyte sedimentation rate, C-reactive protein (CRP), estimated glomerular filtration rate (eGFR), triglycerides, total cholesterol, HDL, LDL, TSH, and urinary albumin-to-creatinine ratio, were retrieved from the hospital information management system and recorded. Subsequently, all patients were referred to the Faculty of Dentistry, Pamukkale University for further periodontal evaluation.
Following periodontal examination, participants were diagnosed as periodontally healthy, gingivitis, or periodontitis, and were allocated to the corresponding study groups according to their periodontal status. The periodontal status of patients was determined based on the Classification of Periodontal and Peri-Implant Diseases and Conditions stated in 2017 World Workshop. Periodontally health was considered if the volunteers have clinically healthy gingiva on an intact periodontium who had BOP < 10% and PD ≤ 3 mm, no sites with attachment loss, no radiographic sign of alveolar bone destruction and no history of periodontitis. Gingivitis was characterized by the absence of clinical attachment loss and radiographic bone loss, with a BOP score ≥10% (gingivitis on an intact periodontium). Patients with periodontitis were defined as individuals presenting with periodontal disease characterized by PD ≥6 mm, interdental clinical attachment loss (CAL) ≥5 mm, and radiographic bone loss extending to the middle third of the root or beyond in ≥30% of teeth. In these patients, the number of teeth lost due to periodontitis was ≤4.
In Endocrinology clinic, peripheral venous blood samples were collected from all included participants via the antecubital vein. A total of 10 mL of venous blood was obtained using separator vacutainer tubes and centrifuged at room temperature. Unstimulated whole saliva was collected by passive drooling into a sterile test tube over a 10-minute period in Periodontology clinic. The collected serum and saliva samples were transferred into Eppendorf tubes and stored at -80°C until the day of analysis.
The concentrations of NGAL, TNF-α, and IL-10 in serum and saliva samples were measured using the enzyme-linked immunosorbent assay (ELISA) method at the Department of Histology and Embryology.
The power analyse of the study was performed for sample size calculation. Sample size was calculated using the G*Power software program (G*Power; Universitat, Dusseldorf, Germany) for α = 0.05 and f = 0.4. The analyses revealed that 19 subjects per group achieved a power of 80 % with 95% confidence.
The data were analysed with the SPSS 25 program (SPSS Inc., Chicago, IL). Continuous variables were presented as mean ± standard deviation and categorical variables as numbers and percentages. Shapiro-Wilk test was used to detect data's normality. For the comparison of the parameters of the study groups, One-way ANOVA test was used for normally distributed data while Kruskal-Wallis test was performed as non-parametric test. For pairwise group comparisons, Student's t-test or the Mann-Whitney U test was applied. Chi-square test was used for the comparison of the categorical variables. Statistical significance value was considered as p < 0.05.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| newly diagnosed type 2 diabetes and periodontal health | – | Diagnostic Test: clinical periodontal measurements, Diagnostic Test: serum samples, Diagnostic Test: saliva samples21 participants with newly diagnosed type 2 diabetes and periodontal health were recruited in group 1. The clinical periodontal parameters taken are as follows: plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL). The present number of teeth in participants was recorded. Serum and saliva samples were collected for the analysis of biomarkers such as NGAL, IL-10, and TNF-α. |
| newly diagnosed type 2 diabetes and gingivitis | – | Diagnostic Test: clinical periodontal measurements, Diagnostic Test: serum samples, Diagnostic Test: saliva samples20 participants with newly diagnosed type 2 diabetes and gingivitis were recruited in group 2. The clinical periodontal parameters taken are as follows: plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL). The present number of teeth in participants was recorded. Serum and saliva samples were collected for the analysis of biomarkers such as NGAL, IL-10, and TNF-α. |
| newly diagnosed type 2 diabetes and periodontitis | – | Diagnostic Test: clinical periodontal measurements, Diagnostic Test: serum samples, Diagnostic Test: saliva samples22 participants with newly diagnosed type 2 diabetes and gingivitis were recruited in group 3. The clinical periodontal parameters taken are as follows: plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL). The present number of teeth in participants was recorded. Serum and saliva samples were collected for the analysis of biomarkers such as NGAL, IL-10, and TNF-α. |
| diabetic nephropathy and periodontal health | – | Diagnostic Test: clinical periodontal measurements, Diagnostic Test: serum samples, Diagnostic Test: saliva samples21 participants with diabetic nephropathy and periodontal health were recruited in group 4. The clinical periodontal parameters taken are as follows: plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL). The present number of teeth in participants was recorded. Serum and saliva samples were collected for the analysis of biomarkers such as NGAL, IL-10, and TNF-α. |
| diabetic nephropathy and gingivitis | – | Diagnostic Test: clinical periodontal measurements, Diagnostic Test: serum samples, Diagnostic Test: saliva samples20 participants with diabetic nephropathy and gingivitis were recruited in group 5. The clinical periodontal parameters taken are as follows: plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL). The present number of teeth in participants was recorded. Serum and saliva samples were collected for the analysis of biomarkers such as NGAL, IL-10, and TNF-α. |
| diabetic nephropathy and periodontitis | – | Diagnostic Test: clinical periodontal measurements, Diagnostic Test: serum samples, Diagnostic Test: saliva samples22 participants with diabetic nephropathy and gingivitis were recruited in group 6. The clinical periodontal parameters taken are as follows: plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL). The present number of teeth in participants was recorded. Serum and saliva samples were collected for the analysis of biomarkers such as NGAL, IL-10, and TNF-α. |
Who may qualify
- Ages
- 20 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Newly diagnosed type 2 diabetic subjects were recruited from patients diagnosed with type 2 diabetes for less than 5 years attending the outpatient clinic of the Department of Endocrinology, Pamukkale University Hospital and subsequently referred to the Department of Periodontology. Following periodontal examination, participants were diagnosed as periodontally healthy, gingivitis, or periodontitis, and were allocated to the corresponding study groups according to their periodontal status.
Key inclusion criteria (2 listed)
- Newly diagnosed diabetes: Diagnosed with type 2 diabetes mellitus for less than 5 years and the absence of any diabetic vascular complications
- Diabetic nephropathy: Urinary albumin-to-creatinine ratio >30 mg/g
Key exclusion criteria (6 listed)
- Having fewer than 15 natural teeth
- Pregnancy or lactation
- History of malignancy
- Use of systemic antibiotics or anti-inflammatory drugs within the 6 months prior to study enrollment
- Periodontal treatment within the previous 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| clinical periodontal measurementsPeriodontal parameters such as PI, GI, BOP, PD, and CAL were measured using the Williams periodontal probe (Hu-Friedy, Chicago IL). PD and CAL were calculated at six surfaces per tooth, whereas PI and GI were measured at four surfaces per tooth. the periodontal status of patients was determined based on the Classification of Periodontal and peri-implant diseases and conditions stated in 2017 World Workshop | Diagnostic test | diabetic nephropathy and gingivitis, diabetic nephropathy and periodontal health, diabetic nephropathy and periodontitis, newly diagnosed type 2 diabetes and gingivitis, newly diagnosed type 2 diabetes and periodontal health, newly diagnosed type 2 diabetes and periodontitis |
| serum samplesPeripheral blood samples were obtained from the antecubital vein. A total of 10 mL of venous blood was collected using separator vacutainer tubes and centrifuged at room temperature. The obtained serum was transferred into separate Eppendorf tubes. The tubes were sealed with parafilm, labeled, and stored at -80°C until the day of analysis. NGAL, TNF-alpha and IL-10 levels were analyzed with ELISA method | Diagnostic test | diabetic nephropathy and gingivitis, diabetic nephropathy and periodontal health, diabetic nephropathy and periodontitis, newly diagnosed type 2 diabetes and gingivitis, newly diagnosed type 2 diabetes and periodontal health, newly diagnosed type 2 diabetes and periodontitis |
| saliva samplesUnstimulated whole saliva samples were collected using the passive drooling method into a sterile collection tube over a 10-minute period.The obtained saliva was transferred into separate Eppendorf tubes. The tubes were sealed with parafilm, labeled, and stored at -80°C until the day of analysis. NGAL, TNF-alpha and IL-10 levels were analyzed with ELISA method | Diagnostic test | diabetic nephropathy and gingivitis, diabetic nephropathy and periodontal health, diabetic nephropathy and periodontitis, newly diagnosed type 2 diabetes and gingivitis, newly diagnosed type 2 diabetes and periodontal health, newly diagnosed type 2 diabetes and periodontitis |
Primary outcome
NGAL analysis
Time frame: baseline
Mean NGAL levels (ng/ml) in serum and saliva
2 secondary outcomes
TNF-alpha analysis
Time frame: baseline
IL-10 analysis
Time frame: baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2026.
Related trials for Diabetic Nephropathy Type 2
Not yet recruitingObservational study
Beta-2-Trace Protein in Diabetic Nephropathy
Diabetic Nephropathy Type 2, Type 2 Diabetes Mellitus
Active, not recruitingObservational study
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
Diabetic Nephropathy, Diabetes Mellitus
Active, not recruitingPhase 2
A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease
Diabetic Kidney Disease (DKD), Type 2 Diabetes
RecruitingPhase 2
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
Diabetic Kidney Disease (DKD)
Not yet recruitingPhase 2
Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring.
Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetic Nephropathy Type 2 and Type 2 Diabetes, run by Pamukkale University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
NGAL analysis (time frame: baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.